The heart in muscular dystrophy

Larry W. Markham, Robert L. Spicer, Linda H. Cripe

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Pediatricians and other healthcare professionals need to be alert to the presence and progression of cardiac involvement in patients with MD. The signs and symptoms of cardiac involvement may be minimal, necessitating careful interval history, physical examination, and noninvasive cardiac testing. Available treatment strategies may reduce disease morbidity and mortality. It is reasonable to expect that a child who has skeletal muscle weakness from MD may have cardiac involvement, even if it is subclinical. Treatment of the muscular dystrophies through genetic engineering is a future dream. However, the improvements in clinical care, evaluation and treatment standards, and multidisciplinary supportive care are able to benefit the current generation of children.

Original languageEnglish (US)
Pages (from-to)531-535
Number of pages5
JournalPediatric Annals
Volume34
Issue number7
DOIs
StatePublished - Jul 2005

Fingerprint

Muscular Dystrophies
Genetic Engineering
Muscle Weakness
Signs and Symptoms
Physical Examination
Skeletal Muscle
Therapeutics
History
Morbidity
Delivery of Health Care
Mortality

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

The heart in muscular dystrophy. / Markham, Larry W.; Spicer, Robert L.; Cripe, Linda H.

In: Pediatric Annals, Vol. 34, No. 7, 07.2005, p. 531-535.

Research output: Contribution to journalReview article

Markham, Larry W. ; Spicer, Robert L. ; Cripe, Linda H. / The heart in muscular dystrophy. In: Pediatric Annals. 2005 ; Vol. 34, No. 7. pp. 531-535.
@article{78b6cfddc5ab447eaca14a2ffc75bbcc,
title = "The heart in muscular dystrophy",
abstract = "Pediatricians and other healthcare professionals need to be alert to the presence and progression of cardiac involvement in patients with MD. The signs and symptoms of cardiac involvement may be minimal, necessitating careful interval history, physical examination, and noninvasive cardiac testing. Available treatment strategies may reduce disease morbidity and mortality. It is reasonable to expect that a child who has skeletal muscle weakness from MD may have cardiac involvement, even if it is subclinical. Treatment of the muscular dystrophies through genetic engineering is a future dream. However, the improvements in clinical care, evaluation and treatment standards, and multidisciplinary supportive care are able to benefit the current generation of children.",
author = "Markham, {Larry W.} and Spicer, {Robert L.} and Cripe, {Linda H.}",
year = "2005",
month = "7",
doi = "10.3928/0090-4481-20050701-10",
language = "English (US)",
volume = "34",
pages = "531--535",
journal = "Pediatric Annals",
issn = "0090-4481",
publisher = "Slack Incorporated",
number = "7",

}

TY - JOUR

T1 - The heart in muscular dystrophy

AU - Markham, Larry W.

AU - Spicer, Robert L.

AU - Cripe, Linda H.

PY - 2005/7

Y1 - 2005/7

N2 - Pediatricians and other healthcare professionals need to be alert to the presence and progression of cardiac involvement in patients with MD. The signs and symptoms of cardiac involvement may be minimal, necessitating careful interval history, physical examination, and noninvasive cardiac testing. Available treatment strategies may reduce disease morbidity and mortality. It is reasonable to expect that a child who has skeletal muscle weakness from MD may have cardiac involvement, even if it is subclinical. Treatment of the muscular dystrophies through genetic engineering is a future dream. However, the improvements in clinical care, evaluation and treatment standards, and multidisciplinary supportive care are able to benefit the current generation of children.

AB - Pediatricians and other healthcare professionals need to be alert to the presence and progression of cardiac involvement in patients with MD. The signs and symptoms of cardiac involvement may be minimal, necessitating careful interval history, physical examination, and noninvasive cardiac testing. Available treatment strategies may reduce disease morbidity and mortality. It is reasonable to expect that a child who has skeletal muscle weakness from MD may have cardiac involvement, even if it is subclinical. Treatment of the muscular dystrophies through genetic engineering is a future dream. However, the improvements in clinical care, evaluation and treatment standards, and multidisciplinary supportive care are able to benefit the current generation of children.

UR - http://www.scopus.com/inward/record.url?scp=23044493089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044493089&partnerID=8YFLogxK

U2 - 10.3928/0090-4481-20050701-10

DO - 10.3928/0090-4481-20050701-10

M3 - Review article

C2 - 16092627

AN - SCOPUS:23044493089

VL - 34

SP - 531

EP - 535

JO - Pediatric Annals

JF - Pediatric Annals

SN - 0090-4481

IS - 7

ER -